Literature DB >> 10518220

Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown.

A F Kisselev1, T N Akopian, V Castillo, A L Goldberg.   

Abstract

In eukaryotes, the 20S proteasome contains two chymotrypsin-like, two trypsin-like, and two active sites shown here to have caspase-like specificity. We report that certain sites allosterically regulate each other's activities. Substrates of a chymotrypsin-like site stimulate dramatically the caspase-like activity and also activate the other chymotrypsin-like site. Moreover, substrates of the caspase-like sites inhibit allosterically the chymotrypsin-like activity (the rate-limiting one in protein breakdown) and thus can reduce the degradation of proteins by 26S proteasomes. These allosteric effects suggest an ordered, cyclical mechanism for protein degradation. We propose that the chymotrypsin-like site initially cleaves ("bites") the polypeptide, thereby stimulating the caspase-like sites. Their activation accelerates further cleavage ("chewing") of the fragments, while the chymotrypsin-like activity is temporarily inhibited. When further caspase-like cleavages are impossible, the chymotryptic site is reactivated and the cycle repeated.

Mesh:

Substances:

Year:  1999        PMID: 10518220     DOI: 10.1016/s1097-2765(00)80341-x

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  76 in total

1.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

2.  Human T-cell leukemia virus type 1 Tax protein binds to assembled nuclear proteasomes and enhances their proteolytic activity.

Authors:  J Hemelaar; F Bex; B Booth; V Cerundolo; A McMichael; S Daenke
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  The kinder side of killer proteases: caspase activation contributes to neuroprotection and CNS remodeling.

Authors:  B McLaughlin
Journal:  Apoptosis       Date:  2004-03       Impact factor: 4.677

4.  The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2011-10-03       Impact factor: 5.911

5.  Peptidomic analysis of HEK293T cells: effect of the proteasome inhibitor epoxomicin on intracellular peptides.

Authors:  Lloyd D Fricker; Julia S Gelman; Leandro M Castro; Fabio C Gozzo; Emer S Ferro
Journal:  J Proteome Res       Date:  2012-02-16       Impact factor: 4.466

Review 6.  The immunoproteasome as a target in hematologic malignancies.

Authors:  Deborah J Kuhn; Robert Z Orlowski
Journal:  Semin Hematol       Date:  2012-07       Impact factor: 3.851

7.  Proteolysis is depressed during torpor in hibernators at the level of the 20S core protease.

Authors:  Vanja Velickovska; Bryan P Lloyd; Safdar Qureshi; Frank van Breukelen
Journal:  J Comp Physiol B       Date:  2005-05-24       Impact factor: 2.200

8.  Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.

Authors:  Cord Naujokat; Carsten Berges; Alexandra Höh; Hubert Wieczorek; Dominik Fuchs; Jörg Ovens; Marion Miltz; Mahmoud Sadeghi; Gerhard Opelz; Volker Daniel
Journal:  Immunology       Date:  2006-11-03       Impact factor: 7.397

9.  A novel class of intrinsic proteasome inhibitory gene transfer peptides.

Authors:  Molly E Martin; Kevin G Rice
Journal:  Bioconjug Chem       Date:  2007-12-21       Impact factor: 4.774

10.  Endoplasmic reticulum stress-induced cell death mediated by the proteasome.

Authors:  L Egger; D T Madden; C Rhême; R V Rao; D E Bredesen
Journal:  Cell Death Differ       Date:  2007-03-30       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.